News

  • 22 October 2012

    Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it would present the latest REDUCE-HTN renal denervation clinical study data at this year’s Transcatheter Cardiovascular Therapeutics (TCT) meeting to be held Oct. 22-26 at the Miami Beach Convention Center in Miami.

  • 17 September 2012

    Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has received approval from Australia’s Therapeutic Goods Administration (TGA) for its V2 Renal Denervation System™ for the treatment of hypertension. Renal denervation is a percutaneous, catheter-based therapy that uses RF energy to disrupt renal sympathetic nerves whose hyperactivity leads to uncontrolled high blood pressure.

  • 28 June 2012

    Proceeds To Advance Development and Commercialize Treatment for Root Canal Therapy

    Sonendo, Inc. (formerly known as Dentatek Corporation), a privately-held company developing disruptive technologies to transform endodontic therapy, announced today that it has agreed to terms for a $20 million equity financing of which $9.2 million has been invested in an initial closing.  The round was led by OrbiMed Advisors, LLC, with NeoMed Management joining existing investors, including Fjord Ventures Management.  The proceeds from the financing will be used to finalize technology development, fund clinical studies and commercialize Sonendo's first endotherapy system.  Vince Burgess of OrbiMed and Erik Amble of NeoMed have joined the company's board of directors. 

  • 13 June 2012

    Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the TOCCASTAR clinical study. TOCCASTAR is a prospective, randomized, multi-center investigational device exemption (IDE) trial designed to evaluate the safety and effectiveness of the company’s TactiCath force-sensing ablation catheter in patients with symptomatic paroxysmal atrial fibrillation (AF).

  • 13 June 2012

    Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that KUR-023, its novel dural sealant product candidate, successfully sealed intra-operative CSF leakage in all evaluable patients.